RxDoctor Payments Data

Lynette Meece, DPM

Podiatrist · Indianapolis, INNPI 1699207282

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (51.4%), food and beverage and other — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Orthofix Medical, Inc. at 29.9% of the total. Reporting peaked in 2019 at $2,070 and has fallen 91.6% since, to $173 in 2025.

$5,430in general payments, 2019–2025

Across 69 payments — averaging $78.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Orthofix Medical, Inc.$2K
  • Smith+Nephew$1K
  • Stryker$824
  • Crossroads Orthopedics, LLC$448
  • Integra Lifesciences Corporation$438
  • Arthrex$206
  • plus $640 from 7 others

What the payments were for

  • Travel & lodging$2,78951%
  • Food & beverage$2,22541%
  • Other$4178%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,430 in reported general payments places this provider in the 75th percentile of 131 podiatrist providers in Indiana.

See all podiatrist providers in Indiana

Medicare billing

Part B allowed, 2024
$52,749
Medicare patients
202
Services billed
607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole22$20,202
Ciclopirox98$2,365
Terbinafine Hcl48$809
Gentamicin Sulfate28$663
Ketoconazole30$439
Pregabalin25$268
Diclofenac Sodium12$243
Gabapentin29$165
Doxycycline Hyclate15$157
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$103
Meloxicam41$101
Methylprednisolone12$90
Mupirocin16$61
Prednisone13$15

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$21$20,20222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 131 podiatrist providers in Indiana.

Other podiatrist in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →